The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - OncLive
Speakers' Bureau - Lilly
Research Funding - Abbvie (Inst); Isofol Medical (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - AstraZeneca
Afatinib as a novel potential treatment option for NRG1 fusion-positive tumors.
 
Janessa J. Laskin
Honoraria - AstraZeneca; Boehringer Ingelheim; Pfizer; Roche Canada
Research Funding - AstraZeneca (Inst); Roche Canada (Inst)
 
Jacques Cadranel
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
Daniel John Renouf
Honoraria - Celgene; Ipsen; SERVIER; Taiho Pharmaceutical
Consulting or Advisory Role - Celgene; SERVIER; Shire
Research Funding - AstraZeneca (Inst); Bayer (Inst)
 
Benjamin A. Weinberg
No Relationships to Disclose
 
Yasushi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Kyorin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Michaël Duruisseaux
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Pfizer
Research Funding - NanoString Technologies (Inst); Novartis (Inst); Pfizer (Inst)
 
Khaled Tolba
No Relationships to Disclose
 
Eva Branden
No Relationships to Disclose
 
Robert Doebele
Stock and Other Ownership Interests - Rain Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; GreenPeptide; Ignyta; OncoMed; Rain Therapeutics; Roche/Genentech; Takeda
Research Funding - Ignyta (Inst)
Patents, Royalties, Other Intellectual Property - Licensing fees for biologic materials from Black Diamond (Inst); Licensing fees for biologic materials from Foundation Medicine (Inst); Licensing fees for biologic materials from Genentech (Inst); Licensing fees for patent from Rain Therapeutics; Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)
Travel, Accommodations, Expenses - Ignyta; Rain Therapeutics; Roche/Genentech
 
Christoph Heining
No Relationships to Disclose
 
Richard F. Schlenk
No Relationships to Disclose
 
Parneet Kaur Cheema
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genomic Health; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genomic Health; Novartis; Pfizer; Roche; Takeda
 
Martin R. Jones
Employment - Qiagen
 
Domenico Trombetta
No Relationships to Disclose
 
Lucia A. Muscarella
No Relationships to Disclose
 
Agnieszka Cseh
Employment - Boehringer Ingelheim
 
Flavio Solca
Employment - Boehringer Ingelheim
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; HERON; Lilly; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Blueprint Medicines; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Lilly; Lycera; Merck; Molecular Partners; OncoMed; Pfizer; Threshold Pharmaceuticals